XM does not provide services to residents of the United States of America.
A
A

Arcadis

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Arcadis Signs New Framework Contract For Dutch Zuidasdok Program

BRIEF-Arcadis Signs New Framework Contract For Dutch Zuidasdok Program Sept 12 (Reuters) - Arcadis NV ARDS.AS : ARCADIS SECURES RENEWED FRAMEWORK CONTRACT FOR DUTCH ZUIDASDOK PROGRAM NEWLY AWARDED CONTRACT SECURES CONTINUED INVOLVEMENT OF IBZ FOR REMAINING DURATION OF PROGRAM, UNTIL 2036 DEAL FOR EUR 105 MLN Source text for Workspace: nNDL9rP81H Fu
A

Rates start reversing, but European small/mid-caps' valuations remain unchanged - Jefferies

BUZZ-Rates start reversing, but European small/mid-caps' valuations remain unchanged - Jefferies ** Jefferies sees investment opportunities among European small- and mid-cap stocks, citing valuations at record lows vs large caps and a broad-based recovery that has not yet materialised, while Eurozone rates have started to reverse ** It says volatil
A
N

Draegerwerk, Hikma, Novartis

EUROPE RESEARCH ROUNDUP-Draegerwerk, Hikma, Novartis Sept 3 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Draegerwerk, Hikma and Novartis, on Tuesday. HIGHLIGHTS * Draegerwerk DRWG.DE : Jefferies raises to hold from underperform * Hikma HIK.L : Berenberg raises to buy from hold * Munters Group AB MTRS.ST : Jefferies raises to buy from hold * Novartis AG NOVN.S : Jefferies cuts to hold from buy * Swedencare AB (Publ) SECARE.ST : J
A
A
A
B
B
B
C
D
G
H
H
N
S
T
U
A
P

TK Alliance Announced As Preferred Proponent For Australia's T2D Project

BRIEF-TK Alliance Announced As Preferred Proponent For Australia's T2D Project Aug 14 (Reuters) - Arcadis NV ARDS.AS : SAID ON TUESDAY: ARCADIS, JOHN HOLLAND, BOUYGUES CONSTRUCTION AUSTRALIA, JACOBS AND VENTIA SELECTED FOR RIVER TORRENS TO DARLINGTON (T2D) PROJECT SOUTH AUSTRALIAN GOVERNMENT $15.4 BLN T2D PROJECT WILL DELIVER 10.5KM OF NON-STOP MOT
A
B

Greencore, UCB, Unilever

EUROPE RESEARCH ROUNDUP-Greencore, UCB, Unilever July 26 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Greencore, UCB, and Unilever, on Friday. HIGHLIGHTS * Greencore GNC.L : HSBC raises target price to 190p from 160p * Lonza Group AG LONN.S : JP Morgan raises target price to CHF 645 from CHF 600 * Sartorius Stedim Biotech STDM.PA : HSBC cuts target price to EUR 310 from EUR 360 * UCB SA UCB.BR : TD Cowen raises target price to E
A
A
A
B
B
B
B
B
C
D
D
E
G
G
G
L
N
N
P
R
S
U
A
A
A
A
A
A
B
D
J

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.